Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

• Status: Recruiting
• Trial end date: 2026-11-23
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy:

SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shinshu University
• Treatments: Denosumab; Diphosphonates

Criteria

Inclusion Criteria:

• osteoporosis patients

Exclusion Criteria:

• not osteoporosis patients who are allergic to the drugs, refused to do this research, or who are pregnant